## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.6% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($218.11)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. AbbVie Stock News Today (Dec. 22, 2025): ABBV Holds Near $227 as Drug-Pricing Talks, Dividend Growth, and 2026 Catalysts Come Into Focus**
- Source: ts2.tech | 20251222T170825 | Neutral | Relevance: 100%
- AbbVie (NYSE: ABBV) is trading near $227, facing policy risks from drug-pricing agreements while also benefiting from strong sales of Skyrizi and Rinvoq, a rising dividend, and a robust pipeline. The immediate focus for investors is on whether AbbVie will join the White House's "most-favored-nation" drug-pricing deals, as it remains one of the few major drugmakers not yet signed. Despite this uncertainty, the company's core immunology franchise and pipeline momentum, coupled with a recently increased quarterly dividend to $1.73, underpin its investment case.

**2. Meadowbrook Wealth Management LLC Purchases New Position in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251221T105135 | Bullish | Relevance: 100%
- Meadowbrook Wealth Management LLC has acquired a new position in AbbVie Inc. (NYSE:ABBV), purchasing 16,589 shares valued at approximately $3.84 million, making it their 5th largest holding. This comes as AbbVie reported strong Q3 earnings, beating analyst expectations, and increased its quarterly dividend. Institutional investors largely own AbbVie stock, and analysts maintain a "Moderate Buy" rating with an average price target of $245.84.

**3. |CCM Investment Advisers LLC Decreases Stock Holdings in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251222T090800 | Somewhat-Bullish | Relevance: 100%
- |CCM Investment Advisers LLC reduced its stake in AbbVie Inc. (NYSE:ABBV) by 9.3% in the third quarter, now holding 73,838 shares valued at $17.097 million. Other institutional investors have also adjusted their holdings in AbbVie, which currently has a "Moderate Buy" consensus rating and a target price of $245.84 from analysts. The company recently increased its quarterly dividend to $1.73 per share, yielding 3.0% annually.

**4. Charles Schwab Trust Co Acquires 15,502 Shares of AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251222T090731 | Somewhat-Bullish | Relevance: 100%
- Charles Schwab Trust Co significantly increased its stake in AbbVie Inc. by 93.4% in the third quarter, purchasing 15,502 shares and raising its total holdings to 32,105 shares, valued at approximately $7.43 million. AbbVie recently announced an increase in its quarterly dividend to $1.73 per share, leading to an annualized dividend of $6.92 and a yield of around 3.0%. The company maintains a "Moderate Buy" consensus rating from analysts, with an average price target of $245.84, following recent upgrades and price target increases from firms like HSBC and Morgan Stanley.

**5. AbbVie Inc. $ABBV Shares Sold by BDF Gestion**
- Source: MarketBeat | 20251221T080729 | Somewhat-Bullish | Relevance: 100%
- BDF Gestion reduced its stake in AbbVie Inc. (NYSE:ABBV) by 17.2%, selling 7,178 shares and retaining 34,522 shares valued at $7.99 million. This makes AbbVie the 19th largest holding in BDF Gestion's portfolio, representing 0.9% of its total investments. The article also notes recent analyst ratings, AbbVie's dividend increase, and its strong earnings performance for the most recent quarter.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $269 | $261 | +3% |
| 2025-12-10 | HSBC | $265 | $225 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Overweight |
| 2025-12-10 | HSBC | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.06M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.41 indicates undervaluation relative to growth. Forward P/E 16.0x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $402.8B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.41 |
| Forward P/E | 16.0 |
| Current P/E | 21.4 |
| YoY Growth | 33.9% |
| EPS Direction | FALLING |

### Technicals

MRS_10 stable at 0.6% (minimal 5-day change). Below STRENGTH zone by 2.4pp (needs >3.0% for momentum thesis). MRS_5 (-0.2%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 53. OFD pattern: +MLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.60% (CS: 63) | Neutral |
| RSI_14 | 52.8 | Neutral |
| MACD Histogram | 0.06 | Bullish |
| vs SMA20 | 1.008x | Above |
| vs SMA50 | 1.005x | Above |
| vs SMA200 | 1.108x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $227.85
- **Stop Loss:** $218.11 (4.3% risk)
- **Target:** $237.59 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 123
- **Position Value:** $28,025.55
- **Portfolio %:** 28.03%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*